Ingredients

DMAE & PABA

During the late 1940s, Romanian cardiologist Dr. Ana Aslan pioneered the use of injectable procaine hydrochloride—a drug—in the treatment of geriatric patients. She discovered inadvertently that procaine—also called Novocaine,® a local anesthetic—not only acts as an analgesic (pain killer), it provides many additional health benefits as well. For decades Dr. Aslan was the director of the National Institute of Gerontology and Geriatrics in Romania, where she dedicated herself to discovering the medical benefits of procaine.

Over the course of many decades Dr. Aslan, her associates, as well as medical clinics throughout the world, performed clinical evaluations of an orally-administered procaine product which came to be called Gerovital H-3. Based on her initial observations of the many varied benefits of H-3, more than 500 clinical studies conducted by leading researchers throughout the world support her findings.

So effective were her treatments for a multiplicity of ailments that, over a period of decades, celebrities and heads of state alike visited her clinic for treatment. John F. Kennedy, Nikita Khrushchev, Charlie Chaplin, as well as many other top government officials and ambassadors were known to have visited her Institute. Dr. Aslan became a legend in her own time, and has been quoted in the following publications: Who’s Who in America (1972), Who’s Who in the World (1971), Who’s Who of Women (1971), British Encyclopedia (1974), Who’s Who of Intellectuals (1976), The International Men of Achievement (1976), and the International Biographical Association of England (1978).

<<<  Back To Previous Page  <<<

The mechanism of procaine’s physiological action is straightforward. Upon digestion, H-3 breaks down into two principal metabolites: para-aminobenzoic acid (PABA) and diethylaminoethanol (DEAE). Essentially, the B-vitamin PABA is linked to a precursor of a B-vitamin, DEAE. The absorption takes place in a competitive manner, meaning the two constituents compete for the active absorption sites or mechanism that govern their absorption. DEAE’s absorption is particular to the brain as compared to other organs. It splits into ethanolamine, glycine and urea. Ethanolamine enters the synthesis cycle of choline and then acetylcholine—a powerful neurotransmitter.

H-3 also participates in the regulation of monoamine oxydase (MAO), an enzyme that catalyzes the breakdown of the monoamine neurotransmitters dopamine, epinephrine and norepinephrine. H-3 aids in preventing these neurotransmitters from being degraded, which enables them to perform their function of helping to maintain a relaxed, positive state of mind. In 1972, researchers reported in The Lancet that beginning at about age 40, an increase in the level of MAO is directly related to the aging process, including depression. As MAO levels rise, neurotransmitter levels fall, leading to a state of senility and depression Additionally, PABA has been shown to increase production of ATP (the body’s “energy chemical”) within cell mitochondria.

The above physiological mechanisms of action account for the main positive effects of procaine, which are: 1) Often produces a mildly-euphoric effect shortly after administration, 2) Reduces anxiety and depression. Helps quell free-floating anxiety. Helps restore sense of joy in everyday life, 3) Increases physical and mental capabilities, 4) Diminishes body rigidity, 5) Diminishes brown (lipofucin) spots and skin growths, 6) Promotes skin, hair and nail growth, 7) Promotes better sleep, 8) Promotes sexual function, 9) Decreases athletic recovery time, 10) Increases muscular strength, 11) Increases joint mobility, 12) Speeds healing of bone fractures, 13) Occasionally reverts hair to more youthful color, 14) Totally non-addictive, 15) Due to the inhibition of the superoxide radical, H-3 is a powerful antioxidant, 16) No adverse side effects.

Procaine is a prescription drug in the United States. However, many gerontology researchers believe its physical and mental benefits can be reproduced by supplementing with a combination of PABA and DMAE. The reasoning is that since the two principal metabolites of procaine are PABA and DEAE, the combination of PABA and DMAE is quite chemically similar. Further, both PABA and DMAE have many individual anti-aging benefits.

DMAE is a naturally-occurring substance found in fish, including salmon, anchovies, and sardines. It is a powerful anti-inflammatory and can “greatly increase the appearance of radiance, tone, and firmness, while decreasing the micro-inflammation in the skin.”[16] Cell membrane degradation has been proposed as one of the prime mechanisms of normal aging. DMAE is a substance known to stabilize cell membranes. It is a precursor to choline and acetylcholine. It is the choline inside cells that is converted to phosphatidylcholine, used in the building and repair of cell membranes and to support the skin’s foundation of collagen and elastin. The well-known Dr. Nicholas Perricone comments on the oral administration of DMAE thusly, “You can see the effects of additional DMAE in the diet after eating all that salmon in the Three-Day Nutritional Face-lift”[17]—one of Perricone’s skin-enhancing programs.

<<<  Back To Previous Page  <<<

DMAE also has a history of use as a treatment for central nervous system disorders. During the 1950, it was a prescription drug used for treating ailments such as attention deficit disorder. It is currently sold over the counter (OTC) as a nutritional supplement for accelerating mental processes, improving concentration, increasing attention span, relieving mild depression, decreasing irritability and hyperactivity, lessening fatigue states, and decreasing “age spots.” PABA is an antioxidant, anti-cross-linking agent, anti-inflammatory, hair color restorer, and flexibility enhancer.

Notes

  1. Cohen, S., Ditman, K.S. “Effects of Gerovital-H3 on Elderly Depressive Patients.” International Symposium of Gerontology, Bucharest, 1972.
  2. Teitel, A., Gane, P., Stroescu, V., Steflea, D., “About the Mechanisms of Procaine.” Studies of Fisiology, Bucharest, 4, pp.351-360, 1962.
  3. Gordon, P., Fudema, A., Abrams, A., “Effects of Romanian and American Procaine Preparations on Certain Physiological Aspects of Aging.” Gerontologist II, 1962, p.9, Gerontologist, 1965, 20, 2, pp. 114-150.
  4. Aslan, Ana; “Gerovital-H3 Therapy in the Prophylaxis of Ageing.” Romanian Journal of Gerontology & Geriatrics. Bucharest, 1,1 pp. 5-15, 1980.
  5. Yau, M.T. “Gerovital-H3, Monoamineoxidase and Brain Monoamines.” Symposium on Theoretic Aspects of Aging, Miami, Florida, 1974.
  6. Parhon, C.I., Ana Aslan, “L’action de la Vitamine H1 et H2 sur la proliferation de la cellule animale.” Bulletin Academy Romania, Bucharest, 9,1, 137, 1957.
  7. Berger, P; “Innocuite du traitment chronique a la procaine chez le rat en croissance.” C.R. So. Biol., 154, 959, 1960.
  8. Verzar, F. “Note on the influence of procaine, PABA and DEAE on the aging of rats.” Basel, Gerontology 3,6, pp. 350-355, 1959.
  9. Aslan, Ana, et al. “Long term treatment with Gerovital-H3 in Albino rats.” Journal of Gerontology, 20,1, 1965.
  10. Aslan Ana, G. Enachescu. “Reseaches on the Anti-thrombophilic activity of Gerovital-H3 treatment.” Romanian Journal of Gerontolgy & Geriatrics, 180, 1, 2, pp. 195-246.
  11. Russu, C et al. “Antioxidant and lipid lowering effect of original procaine based product Gerovital-H3. Book of abstracts.” The 16th Congress of the Internatonal Association of Gerontology, p. 217.
  12. Zung, W.W.K., Wang, H.S. “Clinical trials of Gerovital-H3 in the treatment of depression in the elderly.” 10th Int. Congress of Gerontology, Jerusalem, 1975.
  13. McFarlane, M.D. “Gerovital-H3 therapy; Mechanism of inhibition ofmonoamineoxidase.” Journal of the American Geriatrics Society, XXII/8, pp. 365-371, 1974.
  14. Robinson, D.S. et al. “Aging, monoamine and monoamineoxidase levels,” Lancet, 1, 0290, 1972.
  15. Luth, P. “Aslan therapie mit Gerovital-H3.” Zeitschrift fur Algemenmedizin, 60, 27, pp. 1162-1164, 1984.
  16. Perricone, N. “The Perricone Weight Loss Program.” Life Extension, p. 44, Nov 2005.
  17. Ibid, pp. 121-124
BACK TO PREVIOUS PAGE      |      BACK TO TOP